Prospective and Comparative Evaluation of a Medical Device Composed of a Perineal Probe Connected to a Mobile Application in the Management of Stress Urinary Incontinence.

NCT06285292 · tracked via the Priya Life Science France tracker

Sponsor

Nantes University Hospital

Phase

Not applicable

Started

2024-11-25

Last updated

2026-06-25

Condition(s) studied

Urinary Incontinence

Investigational drug(s) / intervention(s)

EMY

EMY: Patients in the "intervention" group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study

Study summary

Stress urinary incontinence (SUI) affects around 40% of women and has a major impact on quality of life. The gold standard for the treatment of SUI is pelvicfloor rehabilitation, but this presents constraints in terms of availability of healthcare professionals, as well as organization and travel for patients. Innovative devices offer self-training exercises for the pelvicfloor, thus promoting motivation and adherence to treatment. The hypothesis of this study is to prove that the use of a pelvicfloor medical device combined with 2 rehabilitation sessions is not inferior to pelvic-perineal rehabilitation.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

60 Years

Healthy volunteers

Inclusion Criteria: * Patients with moderate, severe or very severe stress urinary incontinence or mixed stress urinary incontinence (according to ICIQ-UI SF questionnaire score: moderate (6-12), severe (13-18) and very severe (19-21)) * Patient aged between 18 and 60 * Patient with a quality of life score measured with the I-QoL questionnaire less than or equal to 70 (score measured from 0 to 100, with poor quality of life: 0-35; average quality of life: 36-70; good quality of life: 71-100) * Not to have given birth in the last 6 months (to avoid post-partum physiological recovery) * Signed informed consent * Effective contraception throughout the study (declarative) * Patient must have a smartphone running at least Android 7 and iOS 12 * Patient must be able to read and write French Exclusion Criteria: * Patients with mild stress urinary incontinence or mixed stress urinary incontinence (ICIQ-UI SF score: mild (1-5)) * Patient with a quality of life score above 70 (according to the I-QoL questionnaire: good quality of life: 71-100) * Patient undergoing other pelvic-perineal rehabilitation during the study period * Patients with neurological disease or congenital malformation, surgically or medically treated urinary incontinence or prolapse, perineal hypoesthesia or local conditions prohibiting the use of an intravaginal catheter * Infection of the bladder or vagina, or any symptoms associated with infection (itching, pain on urination or fever) * Contraindications to the use of the medical device * Anatomy making catheter placement difficult or impossible; in the case of prolapse, specialist advice is recommended. * Hemorrhage * Patients with genitourinary cancer (within the last 5 years) * Patients with extra-urethral "incontinence" (fistula, ectopic ureter) * Patients with severe urinary retention * Patient with vesico-ureteral reflux * Patients with hypoactive bladder * In case of peripheral denervation in the pelvic-perineal area, specialist advice is recommended * Patients wearing a sacral neuromodulation device * Patients in an exclusion period (determined by a previous or current study) * Impossibility of giving the subject clear information (subject in an emergency situation, difficulties in understanding the subject, etc.) * Patient under court protection * Patient under guardianship or curatorship * Pregnancy (positive pregnancy test) * Breastfeeding (as the hormonal impregnation caused by breastfeeding has a negative impact on perineal tone) * Use of Huawei and Oppo smartphones

Primary outcome measure(s)

Urinary symptoms using the ICIQ-UI SF questionnaire — 6 months
The non-inferiority of 2 sessions of pelvic floor rehabilitation associated with the use of the EMY medical device compared with 15 sessions of pelvic floor rehabilitation (gold standard) on the urinary symptoms score at 6 months will be assessed using the ICIQ-UI SF questionnaire.

Trial sites (1)

Facility	City	Region	Status
CHU de Nantes	Nantes	France	Recruiting

More Nantes University Hospital trials in France

Effect of a Driving Pressure Adjustment Procedure for High-Frequency Jet Ventilation in Patients Undergoing Tumor Thermal Ablation in Interventional Radiology Recruiting

Early Assessment of Quadriceps Muscle Recovery by Dynamometry and 3D Ultrasound in Intensive Care Patients Under Invasive Mechanical Ventilation Recruiting

Echocardiography in Nursing Home Recruiting

Cognitive and Metacognitive Remediation in Addiction Treatment. Starting soon

Study to Evaluate the Efficacy of a Polyamine-deficient Diet for Treating Postoperative Pain After Abdominal Surgery Recruiting

Other trials for the same condition

Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence Active, not recruiting

Strategy for Managing Urinary Incontinence With PRP Starting soon

Efficacy of a Video-Based Educational Program on Female Urinary Incontinence Recruiting

Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Recruiting

Tolerance, Use and Performance of the PEASY Urine Collection Device in Hospitalized Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06285292 on ClinicalTrials.gov ↗ ← All trials in France